The startup develops medical devices that utilize electroporation technology for endoscopic cancer treatment, enabling the painless delivery of pulse field ablation. This approach enhances treatment efficacy and improves patient experiences by facilitating safer and more efficient cancer therapies.
Funding
$35.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments for gastrointestinal and cutaneous tumors often lack precision, leading to damage of healthy tissue and significant side effects for patients. Many existing therapies also require lengthy hospital stays and may not be repeatable or suitable for patients with comorbidities.
Solution
Mirai Medical offers ePORE® therapy, a platform technology that utilizes pulsed electrical fields to selectively ablate tumor tissue while preserving surrounding healthy tissue. The ePORE® system delivers short-duration electrical pulses to permeabilize cancer cell membranes, leading to cell death without thermal damage. The company provides two delivery systems: EndoVE®, an endoscopic probe for gastrointestinal cancers, and CUTIS, an electrode for cutaneous tumors. ePORE® therapy can be administered as a day-case procedure under local anesthesia, reducing hospitalization time and enabling repeatable treatment.
Target Audience
The primary target audience includes clinicians specializing in gastroenterology and dermatology, as well as patients with gastrointestinal and cutaneous solid tumors seeking minimally invasive treatment options.
Features
- ePORE® therapy uses pulsed electrical fields to permeabilize cancer cell membranes, inducing non-thermal tumor ablation.
- EndoVE® is an endoscopic probe designed for safe application of pulsed electrical fields to gastrointestinal tissue, compatible with standard endoscopes.
- EndoVE® features a vacuum chamber to draw the tumor into contact with the electrodes for targeted treatment of oesophageal, gastric, and colorectal cancers.
- CUTIS is a skin electrode designed for ease of use and adaptability in treating subcutaneous and cutaneous skin cancers, including non-melanoma skin cancers, metastatic melanoma, and cutaneous metastases.
- CUTIS has a slider deployment mechanism for effective delivery of pulsed electric fields to the tissue.
- ePORE® therapy preserves healthy tissue, reducing side effects and improving cosmetic outcomes.
- The treatment can be used in conjunction with other standard treatments like chemotherapy and surgery.